On Thursday, ResMed Inc (NYSE:RMD) reported that second-quarter fiscal 2026 adjusted earnings of 2.81, beating the consensus of $2.72.Quarterly sales increased 11$1.42 billion, surpassing the consensus estimate of $1.396 billion.Sales increased 9% on a constant currency basis, driven by increased demand for our portfolio of sleep devices, masks, and accessories.Residential Care Software revenue increased by 5% on a constant currency basis.In December 2025, the U.S. Food and Drug Administ ...